Harmony Biosciences Holdings, Inc.
HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmonyā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$35.56
Price+0.62%
$0.22
1Y
Price
Market Cap
$2.045b
Mid
Price/Earnings 3y Avg5y Avg
11.2x
Premium
Premium
Financials Overview
Key metrics over the past few years+30.7%
EBITDA Margin+21.2%
Net Profit Margin+45.4%
Free Cash Flow MarginRevenue
$825.944m
+15.6%
1y CAGR+23.8%
3y CAGR+28.7%
5y CAGREarnings
$185.676m
+27.6%
1y CAGR+3.9%
3y CAGR+109.0%
5y CAGREPS
$3.18
+26.7%
1y CAGR+5.4%
3y CAGR+107.1%
5y CAGRBook Value
$835.123m
$1.208b
Assets$373.095m
Liabilities$169.734m
DebtDebt to Assets
14.1%
0.6x
Debt to EBITDAFree Cash Flow
$296.894m
+35.8%
1y CAGR+29.1%
3y CAGR+33.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company